Madrigal Pharmaceuticals Surges to 222nd in Daily Rankings with $451 Million Turnover

Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) on July 16, 2025, saw a significant surge in trading volume, with a turnover of $451 million, marking a 429.16% increase from the previous day. This substantial rise in trading activity placed Madrigal at the 222nd position in the daily stock market rankings. The company's stock price also experienced a notable increase, rising by 10.87%.

Madrigal Pharmaceuticals, Inc. announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for Rezdiffra™ (resmetirom), the first and only FDA-approved treatment for adults with noncirrhotic MASH (also known as NASH) with moderate to advanced liver fibrosis. This patent provides protection through September 30, 2044, and will be listed in the FDA’s Orange Book. The Notice of Allowance includes claims directed to Rezdiffra’s commercial weight-threshold dosing regimen as prescribed in the FDA-approved label. This development is a significant milestone for Madrigal, recognizing the value of their pioneering clinical development program and allowing the company to continue driving innovation for patients with MASH for years to come.